摘要
伊班膦酸钠为三代含氮双磷酸盐,已被临床应用于治疗恶性肿瘤骨转移及继发的骨相关事件。伊班膦酸钠同时具有口服和静脉两种剂型,临床试验证实二者均能有效降低骨相关事件的发生率、减轻骨转移所致骨痛的程度、改善骨转移病人的生活质量。在安全性评价方面,伊班膦酸钠具有突出的肾脏安全性,即使采用负荷剂量仍然表现出良好的耐受性。本篇综述主要介绍伊班膦酸钠在治疗骨转移瘤方面的有效性和安全性。
Ibandronate, a nitrogen-containing bisphosphonate, has been used for the treatment of metastatic bone disease and skeletal complications of bone metastases. Intravenous and oral formulations of ibandronate can lower the incidence of skeletal-related events, decrease metastatic bone pain scores, and improve quality of life. Intravenously administered bisphosphonates has good renal safety. Recent pilot studies have suggested that a loading dose of ibandronate relieve severe or opioid- resistant metastatic bone pain. In some safety analyses, ibandronate was well tolerated with a safety profile comparable to placebo. Ibandronate therefore represents a treatment option with documented effieacy and safety in metastatic bone disease from cancer.
出处
《癌症进展》
2008年第1期11-15,共5页
Oncology Progress
关键词
伊班膦酸钠
恶性肿瘤
骨转移
治疗
Ibandronate malignant tumor bone metastasis treatment
